Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Status:
Recruiting
Trial end date:
2022-02-23
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multiple dose, phase II study to assess safety,
tolerability and clinical efficacy of DFV890 in participants with FCAS.
The study includes a screening period, a treatment period and a follow-up period. At most,
the study will last approximately 4 months.